News

The U.S. Food and Drug Administration has approved a triple combination treatment developed by  GlaxoSmithKline as a maintenance therapy for chronic obstructive pulmonary disease. GSK collaborated with Innoviva on the COPD combo, which consists of fluticasone furoate, umeclidinium and vilanterol. The approval means the once-a-day, single-inhaler therapy will enter the U.S. market under the brand…

Chiesi recently completed a long-term study showing that its extra-fine, fixed-dose, triple combination inhaler Trimbow is more effective than Utibron (indacaterol and glycopyrronium) as a therapy for chronic obstructive pulmonary disease (COPD). Trimbow contains the anti-inflammatory inhaled corticosteroid (ICS) beclomethasone dipropionate and two bronchodilators, the long-acting beta2 agonist (LABA) formoterol fumarate and the…

A triple combination inhaler for people with moderate to severe adult chronic obstructive pulmonary disease (COPD) was recommended for approval and use across the European Union this week by CHMP, the scientific arm of the European Medicines Agency’s (EMA). CHMP’s official name is the Committee for Medicinal Products for Human Use.

A combination of Verona Pharma’s COPD therapy candidate RPL554 and Spiriva (tiotropium) significantly improved patients’ lung function and appeared to ease their breathing difficulties, Phase 2a clinical trial results showed. The double-blind, placebo-controlled study (NCT03028142) looked at the combo’s ability to benefit 30 people with chronic obstructive pulmonary disease. Patients received…

INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) showed promising results in a Phase 2 clinical trial, Bellerophon Therapeutics, the clinical-stage company developing the INOpulse program, announced. INOpulse is a portable nitric oxide delivery system being developed for the treatment of PH-COPD. Nitric oxide…

A new study has shown that a minimally invasive procedure involving one-way valves can improve lung function in patients with severe emphysema in a multi-center clinical trial. The study titled, “A Multicenter RCT of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM),” was published in the American Thoracic Society’s…

Pulmatrix has licensed PUR0200, its investigative inhaled treatment for people with chronic obstructive pulmonary disease (COPD), to the Vectura Group to speed its entry into the U.S. market. Vectura, a company specialized in inhaled airway products, will now be responsible for all future development costs to advance the product in the…

An allergic sensitization to the Aspergillus fumigatus fungus may lead to bronchiectasis in patients with chronic obstructive pulmonary disease (COPD), Belgian researchers suggest. The study, “Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD,” was published in the International Journal of Chronic Obstructive Pulmonary…

A new computer model based on anatomical and experimental information can predict changes in lung function caused by chronic inflammation. Developed by researchers at Rutgers University in New Jersey, this virtual system can help identify the different damaging and remodeling factors that contribute to lung function changes in several respiratory…

Propeller Health and GlaxoSmithKline (GSK) will extend their collaboration in which patients with chronic obstructive pulmonary disease (COPD) and asthma use Propeller’s clip-on sensor and software platform with GSK’s Ellipta Inhaler to help them manage their illnesses. The new extended partnership, first announced in 2015, will allow Propeller and GSK to…